190 related articles for article (PubMed ID: 38731812)
1. Assessment of the Correlation and Diagnostic Accuracy between Cerebrospinal Fluid and Plasma Alzheimer's Disease Biomarkers: A Comparison of the Lumipulse and Simoa Platforms.
Dakterzada F; Cipriani R; López-Ortega R; Arias A; Riba-Llena I; Ruiz-Julián M; Huerto R; Tahan N; Matute C; Capetillo-Zarate E; Piñol-Ripoll G
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731812
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic performance of plasma pTau
Arranz J; Zhu N; Rubio-Guerra S; Rodríguez-Baz Í; Ferrer R; Carmona-Iragui M; Barroeta I; Illán-Gala I; Santos-Santos M; Fortea J; Lleó A; Tondo M; Alcolea D
Alzheimers Res Ther; 2024 Jun; 16(1):139. PubMed ID: 38926773
[TBL] [Abstract][Full Text] [Related]
3. Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease.
Leitão MJ; Silva-Spínola A; Santana I; Olmedo V; Nadal A; Le Bastard N; Baldeiras I
Alzheimers Res Ther; 2019 Nov; 11(1):91. PubMed ID: 31759396
[TBL] [Abstract][Full Text] [Related]
4. Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer's Disease from Frontotemporal Lobar Degeneration.
Ortner M; Goldhardt O; Diehl-Schmid J; Yakushev I; Lanz K; Hedderich DM; Manuilova E; Simon M; Weinberger JP; Grimmer T
J Prev Alzheimers Dis; 2022; 9(3):491-498. PubMed ID: 35841250
[TBL] [Abstract][Full Text] [Related]
5. Performance of the Lumipulse plasma Aβ42/40 and pTau181 immunoassays in the detection of amyloid pathology.
Figdore DJ; Wiste HJ; Bornhorst JA; Bateman RJ; Li Y; Graff-Radford J; Knopman DS; Vemuri P; Lowe VJ; Jr CRJ; Petersen RC; Algeciras-Schimnich A
Alzheimers Dement (Amst); 2024; 16(1):e12545. PubMed ID: 38304322
[TBL] [Abstract][Full Text] [Related]
6. Exploring the potential of fully automated LUMIPULSE G plasma assays for detecting Alzheimer's disease pathology.
Silva-Spínola A; Leitão MJ; Nadal A; Le Bastard N; Santana I; Baldeiras I
Alzheimers Res Ther; 2024 Mar; 16(1):51. PubMed ID: 38454502
[TBL] [Abstract][Full Text] [Related]
7. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
[TBL] [Abstract][Full Text] [Related]
8. Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Aβ
Bayart JL; Hanseeuw B; Ivanoiu A; van Pesch V
J Neurol; 2019 Sep; 266(9):2304-2311. PubMed ID: 31179518
[TBL] [Abstract][Full Text] [Related]
9. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
11. CSF and plasma Aβ42/40 across Alzheimer's disease continuum: comparison of two ultrasensitive Simoa
Wojdała AL; Bellomo G; Toja A; Gaetani L; Parnetti L; Chiasserini D
Clin Chem Lab Med; 2024 Jan; 62(2):332-340. PubMed ID: 37656487
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of plasma Aβ40, Aβ42, and p-tau181 to detect CSF Alzheimer's pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform.
Martínez-Dubarbie F; Guerra-Ruiz A; López-García S; Lage C; Fernández-Matarrubia M; Infante J; Pozueta-Cantudo A; García-Martínez M; Corrales-Pardo A; Bravo M; López-Hoyos M; Irure-Ventura J; Sánchez-Juan P; García-Unzueta MT; Rodríguez-Rodríguez E
Alzheimers Res Ther; 2023 Oct; 15(1):163. PubMed ID: 37784138
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest.
Dakterzada F; López-Ortega R; Arias A; Riba-Llena I; Ruiz-Julián M; Huerto R; Tahan N; Piñol-Ripoll G
Front Aging Neurosci; 2021; 13():604119. PubMed ID: 33746733
[TBL] [Abstract][Full Text] [Related]
14. Concordance of Lumipulse cerebrospinal fluid t-tau/Aβ42 ratio with amyloid PET status.
Kaplow J; Vandijck M; Gray J; Kanekiyo M; Huyck E; Traynham CJ; Esquivel R; Fagan AM; Luthman J
Alzheimers Dement; 2020 Jan; 16(1):144-152. PubMed ID: 31914216
[TBL] [Abstract][Full Text] [Related]
15. Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment.
Baldeiras I; Santana I; Leitão MJ; Gens H; Pascoal R; Tábuas-Pereira M; Beato-Coelho J; Duro D; Almeida MR; Oliveira CR
Alzheimers Res Ther; 2018 Mar; 10(1):33. PubMed ID: 29558986
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Commonly Measured Plasma and Cerebrospinal Fluid Proteins and Their Significance for the Characterization of Cognitive Impairment Status.
Rehman H; Ang TFA; Tao Q; Espenilla AL; Au R; Farrer LA; Zhang X; Qiu WQ;
J Alzheimers Dis; 2024; 97(2):621-633. PubMed ID: 38143358
[TBL] [Abstract][Full Text] [Related]
17. Effects of time of the day at sampling on CSF and plasma levels of Alzheimer' disease biomarkers.
Orduña Dolado A; Stomrud E; Ashton NJ; Nilsson J; Quijano-Rubio C; Jethwa A; Brum WS; Brinkmalm Westman A; Zetterberg H; Blennow K; Janelidze S; Hansson O
Alzheimers Res Ther; 2024 Jun; 16(1):132. PubMed ID: 38909218
[TBL] [Abstract][Full Text] [Related]
18. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid.
Harari O; Cruchaga C; Kauwe JS; Ainscough BJ; Bales K; Pickering EH; Bertelsen S; Fagan AM; Holtzman DM; Morris JC; Goate AM;
Biol Psychiatry; 2014 May; 75(9):723-31. PubMed ID: 24548642
[TBL] [Abstract][Full Text] [Related]
20. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
